Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Completed · Phase 1/Phase 2
Conditions studied: Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
In brief
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Key facts
- Study ID
- NCT00809276
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 92
- Starts
- 2009-05-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2015-02-16
Who can join
Age: any, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients ages between 0 to and 65 years of age.
- Patient must have a genotypically HLA-identical sibling, a phenotypically matched first-degree relative or an unrelated matched donor.
- Acute lymphocytic leukemia (ALL) in CR1 with high risk features
- Acute myeloid leukemia (AML) in CR1 with high risk features defined as:
- i. Greater than 1 cycle of induction therapy required to achieve remission, ii. Preceding myelodysplastic syndrome (MDS) other than myelofibrosis, secondary AML iii. Presence of Flt3 mutations or internal tandem duplications, iv. FAB M6 or M7 classification or adverse cytogenetics for overall survival such as those associated with MDS, M6, M7 leukemia, or v. Complex karyotype [> 3 abnormalities]
- Acute Leukemias in 2nd or greater remission
- Refractory or Relapsed AML
- AML transformed from MDS
- Myelodysplastic syndrome (MDS) beyond refractory anemia
- Chronic myeloid leukemia (CML)
- Chronic myelomonocytic leukemia
- Philadelphia-negative myeloproliferative disorder
- Relapsed chemotherapy-sensitive Hodgkin's or Non-Hodgkin's lymphoma
- Multiple Myeloma-Stage III
You may not qualify if…
- Prior autologous or allogeneic stem cell transplant.
- Performance status greater than 2
- Active infection.
- Inadequate cardiac function; arrythmias or symptomatic cardiac disease.
- Inadequate pulmonary function; FEV1, FVC, DLCO <50% of predicted
- Inadequate Serum creatinine clearance <60
- InadequatebHepatic function
- Positive serology for HIV-1, 2 or HTLV-1, 2.
- Pregnancy. Female patient must have negative pregnancy test
Where it is running
- The Sydney Kimmel Comprehensive Cancer center — Baltimore, Maryland, United States
- Marcos deLima, MD — Houston, Texas, United States
- Paul V. O'Donnell, M.D., Ph.D. — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.